Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator eftilagimod alpha (efti) with avelumab in patients with advanced solid tumours. Avelumab is the big pharma pair’s investigational anti-PD-L1 immune checkpoint inhibitor (ICI). We view the additional validation from big pharma is as a very positive development for Immutep, which could bring the added bonus of early identification of additional target indications. We maintain our valuation at A$510m or A$0.17/share.
Written by
Immutep |
A second big pharma collaboration for efti |
Merck/Pfizer collaboration |
Pharma & biotech |
27 September 2018 |
Share price performance
Business description
Next events
Analysts
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator eftilagimod alpha (efti) with avelumab in patients with advanced solid tumours. Avelumab is the big pharma pair’s investigational anti-PD-L1 immune checkpoint inhibitor (ICI). We view the additional validation from big pharma is as a very positive development for Immutep, which could bring the added bonus of early identification of additional target indications. We maintain our valuation at A$510m or A$0.17/share.
Year end |
Revenue |
PBT* |
EPS* |
DPS* |
P/E |
Yield |
06/17 |
4.1 |
(8.4) |
(0.4) |
0.0 |
N/A |
N/A |
06/18 |
6.9 |
(10.9) |
(0.5) |
0.0 |
N/A |
N/A |
06/19e |
10.9 |
(6.8) |
(0.2) |
0.0 |
N/A |
N/A |
06/20e |
2.8 |
(14.9) |
(0.5) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding exceptional items.
Additional validation from big pharma
Immutep already has an ongoing clinical trial collaboration with the US-based Merck and Company (known as MSD outside the US), which is totally separate from Merck KGaA, including the TACTI-mel and TACTI-002 studies. It now has the additional validation of having a second big pharma team review the efti data and conclude that there is a potentially meaningful benefit from efti/ICI combination therapy. The encouraging results from the first three TACTI-mel cohorts included a 33% response rate from the start of efti/Keytruda combination therapy and 61% response rate from the start of the Keytruda monotherapy screening period.
Avelumab combination to be added to INSIGHT trial
The study of avelumab plus subcutaneous (SC) efti in patients with a range of advanced solid tumours will be included as an arm of the INSIGHT study (NCT03252938), which is underway at a single site in Germany. The combination would fit neatly into INSIGHT, which already includes arms investigating intra-tumoural and intraperitoneal administration of efti, as well as a third arm investigating SC efti in combination with chemo in solid tumours. This strategy should allow the efti/avelumab combination study to start before the end of CY18.
Competitive tension a potential added bonus
Having a deep level of engagement with two big pharma companies (or three counting Pfizer) could bring the added bonus of increased competitive tension when the time comes to negotiate a partnership deal for efti.
Valuation: Unchanged at A$510m, 17c per share
Our valuation is unchanged at A$510m, 17c/share (undiluted), or 12c/share after diluting for options and convertible notes. Our valuation includes a modest allowance for expansion of efti indications beyond the ongoing studies in breast, head and neck, melanoma and lung cancers. Gross cash at 30 June was A$23.5m. We assume Immutep will receive a risk-adjusted US$6m IMP731 milestone payment from GSK in FY19, which would extend its cash reach to the end of FY20.
Exhibit 1: Financial summary
A$000s |
2016 |
2017 |
2018 |
2019e |
2020e |
||
Year-end 30 June |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|||||||
Revenue |
|
|
1,949 |
4,117 |
6,854 |
10,898 |
2,778 |
R&D expenses |
(7,060) |
(7,526) |
(9,990) |
(10,990) |
(10,440) |
||
SG&A expenses |
(6,983) |
(4,347) |
(7,242) |
(7,459) |
(7,683) |
||
EBITDA |
|
|
(12,093) |
(7,756) |
(11,435) |
(7,551) |
(15,345) |
Operating Profit (before GW and except.) |
|
(12,275) |
(7,770) |
(11,446) |
(7,554) |
(15,350) |
|
Intangible Amortisation |
(1,993) |
(1,688) |
(1,798) |
(1,650) |
(1,501) |
||
Exceptionals |
(47,468) |
0 |
0 |
0 |
0 |
||
Operating Profit |
(61,736) |
(9,458) |
(13,244) |
(9,204) |
(16,851) |
||
Other |
(1,716) |
(752) |
323 |
0 |
0 |
||
Net Interest |
256 |
104 |
177 |
704 |
498 |
||
Profit Before Tax (norm) |
|
|
(13,735) |
(8,417) |
(10,946) |
(6,850) |
(14,851) |
Profit Before Tax (IFRS) |
|
|
(63,196) |
(10,105) |
(12,744) |
(8,500) |
(16,352) |
Tax |
1,181 |
737 |
(2) |
0 |
0 |
||
Profit After Tax (norm) |
(12,554) |
(7,680) |
(10,948) |
(6,850) |
(14,851) |
||
Profit After Tax (IFRS) |
(62,015) |
(9,368) |
(12,746) |
(8,500) |
(16,352) |
||
Average Number of Shares Outstanding (m) |
2,016.6 |
2,072.5 |
2,079.7 |
3,026.1 |
3,026.1 |
||
EPS - normalised (c) |
|
|
(0.6) |
(0.4) |
(0.5) |
(0.2) |
(0.5) |
EPS - IFRS (c) |
|
|
(3.1) |
(0.5) |
(0.6) |
(0.3) |
(0.5) |
Dividend per share (c) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Gross Margin (%) |
N/A |
N/A |
N/A |
N/A |
N/A |
||
EBITDA Margin (%) |
N/A |
N/A |
N/A |
N/A |
N/A |
||
Operating Margin (before GW and except.) (%) |
N/A |
N/A |
N/A |
N/A |
N/A |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
20,883 |
19,045 |
18,356 |
16,715 |
15,223 |
Intangible Assets |
20,852 |
19,020 |
18,329 |
16,680 |
15,178 |
||
Tangible Assets |
32 |
24 |
26 |
36 |
45 |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Current Assets |
|
|
21,671 |
15,919 |
28,643 |
21,784 |
6,924 |
Stocks |
0 |
0 |
0 |
0 |
0 |
||
Debtors |
168 |
2,194 |
3,432 |
3,432 |
3,432 |
||
Cash |
20,880 |
12,237 |
23,476 |
16,616 |
1,756 |
||
Other |
623 |
1,488 |
1,736 |
1,736 |
1,736 |
||
Current Liabilities |
|
|
(1,472) |
(2,632) |
(3,853) |
(3,853) |
(3,853) |
Creditors |
(1,444) |
(2,589) |
(3,664) |
(3,664) |
(3,664) |
||
Short term borrowings |
(0) |
(0) |
0 |
0 |
0 |
||
Short term leases |
0 |
0 |
0 |
0 |
0 |
||
Other |
(28) |
(43) |
(190) |
(190) |
(190) |
||
Long Term Liabilities |
|
|
(5,765) |
(5,799) |
(9,623) |
(9,623) |
(9,623) |
Long term borrowings incl. conv. note |
(5,027) |
(5,779) |
(6,646) |
(6,646) |
(6,646) |
||
Long term leases |
0 |
0 |
0 |
0 |
0 |
||
Other long term liabilities |
(737) |
(20) |
(2,978) |
(2,978) |
(2,978) |
||
Net Assets |
|
|
35,317 |
26,532 |
33,522 |
25,022 |
8,670 |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
(11,594) |
(8,611) |
(7,954) |
(7,551) |
(15,345) |
Net Interest |
284 |
104 |
177 |
704 |
498 |
||
Tax |
0 |
0 |
0 |
0 |
0 |
||
Capex |
(27) |
(7) |
(12) |
(12) |
(13) |
||
Acquisitions/disposals |
130 |
0 |
0 |
0 |
0 |
||
Financing |
27,229 |
(9) |
18,898 |
0 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
(493) |
0 |
0 |
||
Net Cash Flow |
16,022 |
(8,522) |
10,616 |
(6,859) |
(14,860) |
||
Opening net debt/(cash) |
|
|
(5,251) |
(15,852) |
(6,458) |
(16,830) |
(9,970) |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
||
Other |
(5,421) |
(872) |
(244) |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(15,852) |
(6,458) |
(16,830) |
(9,970) |
4,889 |
Source: Immutep accounts, Edison Investment Research
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US |
Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US |
Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia |
Research: Healthcare
Formycon has reported record H118 revenues, boosted by the one-off transfer of FYB202 into a joint venture with Aristo Pharma and payments stemming from the out-licensed assets FYB201 and FYB203. We believe that Formycon biosimilars FYB201 (Lucentis) and FYB203 (Eylea) are set to enter neovascular age-related macular degeneration (nAMD) market post-2020. Cash and equivalents at end-H118 were €11.8m and should give a cash runaway until 2020 based on H118 cash burn. Formycon guides for FY18 revenues of €35m.